Literature DB >> 21513699

PRAJA1 is a ubiquitin ligase for the polycomb repressive complex 2 proteins.

Muhammad Zoabi1, Ronen Sadeh, Prim de Bie, Victor E Marquez, Aaron Ciechanover.   

Abstract

Methylation of lysine 27 on histone H3 by the polycomb repressive complex 2 (PRC2) leads to transcriptional repression of genes which are critical to development. PRC2 core complex is composed of the histone methyltransferase EZH2, EED, and SUZ12. Knockdown of any of the PRC2 core subunits results in a concomitant loss of the other subunits which is mediated by the ubiquitin (Ub)-proteasome system (UPS). Inhibition of cellular methyltransferases by 3-deazaneplanocin A (DZNep) also leads to dissociation of the PRC2 complex and rapid degradation of its subunits. Interestingly, the expression of several Ub ligases was induced following DZNep treatment, suggesting that PRC2 might repress the Ub ligase(s) that target its subunits for degradation. Here we confirm that individual PRC2 subunits are ubiquitinated and rapidly degraded by the proteasome. One of the DZNep-induced Ub ligases, PRAJA1, can target PRC2 subunits for proteasomal degradation. PRAJA1 directly ubiquitinates individual PRC2 subunits in a cell free system, which leads to their proteasomal degradation. Expression of PRAJA1 but not of an inactive RING finger mutant of the protein, enhanced the degradation of individual PRC2 subunits in cells. Taken together, our results suggest a role for PRAJA1 in regulating the level of PRC2 by targeting its free subunits for Ub-mediated proteasomal degradation.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21513699     DOI: 10.1016/j.bbrc.2011.04.025

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  28 in total

Review 1.  Regulation and role of post-translational modifications of enhancer of zeste homologue 2 in cancer development.

Authors:  Haiqi Lu; Guangliang Li; Chenyi Zhou; Wei Jin; Xiaoling Qian; Zhuo Wang; Hongming Pan; Hongchuan Jin; Xian Wang
Journal:  Am J Cancer Res       Date:  2016-12-01       Impact factor: 6.166

2.  Targeting NEK2 attenuates glioblastoma growth and radioresistance by destabilizing histone methyltransferase EZH2.

Authors:  Jia Wang; Peng Cheng; Marat S Pavlyukov; Hai Yu; Zhuo Zhang; Sung-Hak Kim; Mutsuko Minata; Ahmed Mohyeldin; Wanfu Xie; Dongquan Chen; Violaine Goidts; Brendan Frett; Wenhao Hu; Hongyu Li; Yong Jae Shin; Yeri Lee; Do-Hyun Nam; Harley I Kornblum; Maode Wang; Ichiro Nakano
Journal:  J Clin Invest       Date:  2017-07-24       Impact factor: 14.808

3.  Molecular mechanisms involved in the synergistic interaction of the EZH2 inhibitor 3-deazaneplanocin A with gemcitabine in pancreatic cancer cells.

Authors:  Amir Avan; Francesco Crea; Elisa Paolicchi; Niccola Funel; Elena Galvani; Victor E Marquez; Richard J Honeywell; Romano Danesi; Godefridus J Peters; Elisa Giovannetti
Journal:  Mol Cancer Ther       Date:  2012-05-23       Impact factor: 6.261

Review 4.  Walk the Line: The Role of Ubiquitin in Regulating Transcription in Myocytes.

Authors:  Vidyani Suryadevara; Monte S Willis
Journal:  Physiology (Bethesda)       Date:  2019-09-01

5.  Proteomic Analysis of Endothelin-1 Targets in the Regulation of Cardiomyocyte Proliferation.

Authors:  Alexandra N Shin; Chiranjib Dasgupta; Guangyu Zhang; Kala Seal; Lubo Zhang
Journal:  Curr Top Med Chem       Date:  2017       Impact factor: 3.295

6.  Hsp90 inhibition destabilizes Ezh2 protein in alloreactive T cells and reduces graft-versus-host disease in mice.

Authors:  Qingrong Huang; Shan He; Yuanyuan Tian; Yuting Gu; Pan Chen; Changhong Li; Jiefang Huang; Yongnian Liu; Hongshuang Yu; Min Jin; Shaoyan Hu; Qing Tong; Anqi Ma; Jian Jin; Elizabeth Hexner; Henry Fung; Ran Reshef; Yi Zhang; Yanyun Zhang
Journal:  Blood       Date:  2017-02-28       Impact factor: 22.113

7.  Superior efficacy of a combined epigenetic therapy against human mantle cell lymphoma cells.

Authors:  Warren Fiskus; Rekha Rao; Ramesh Balusu; Siddhartha Ganguly; Jianguo Tao; Eduardo Sotomayor; Uma Mudunuru; Jacqueline E Smith; Stacey L Hembruff; Peter Atadja; Victor E Marquez; Kapil Bhalla
Journal:  Clin Cancer Res       Date:  2012-08-29       Impact factor: 12.531

8.  SKP2 loss destabilizes EZH2 by promoting TRAF6-mediated ubiquitination to suppress prostate cancer.

Authors:  W Lu; S Liu; B Li; Y Xie; M G Izban; B R Ballard; S A Sathyanarayana; S E Adunyah; R J Matusik; Z Chen
Journal:  Oncogene       Date:  2016-11-21       Impact factor: 9.867

9.  YC-1 inhibits proliferation of breast cancer cells by down-regulating EZH2 expression via activation of c-Cbl and ERK.

Authors:  Ling-Chu Chang; Hui-Yi Lin; Meng-Tung Tsai; Ruey-Hwang Chou; Fang-Yu Lee; Che-Ming Teng; Min-Tsang Hsieh; Hsin-Yi Hung; Li-Jiau Huang; Yung-Luen Yu; Sheng-Chu Kuo
Journal:  Br J Pharmacol       Date:  2014-07-25       Impact factor: 8.739

10.  Praja1 ubiquitin ligase facilitates degradation of polyglutamine proteins and suppresses polyglutamine-mediated toxicity.

Authors:  Baijayanti Ghosh; Susnata Karmakar; Mohit Prasad; Atin K Mandal
Journal:  Mol Biol Cell       Date:  2021-06-23       Impact factor: 4.138

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.